Last updated on December 2018

Stage 1 Study of ARALAST NP and GLASSIA in A1PI


Brief description of study

The purpose of this study is to conduct a pilot study to evaluate the safety and efficacy of weekly administration of Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy in subjects with A1PI deficiency and emphysema/ Chronic obstructive pulmonary disease (COPD).

Clinical Study Identifier: NCT02722304

Contact Investigators or Research Sites near you

Start Over

Marc Buggelsheim, PhD

Pulmonary Disease Specialists, P.A., / PDS Research
Kissimmee, FL United States

Marc Buggelsheim, PhD

L&C Professional Medical Research Institute
Miami, FL United States

Marc Buggelsheim, PhD

Hope Clinical Trials
Miami, FL United States

Marc Buggelsheim, PhD

Eminence Medical & Clinical Research
Tampa, FL United States

Marc Buggelsheim, PhD

Indiana University Health
Indianapolis, IN United States

Marc Buggelsheim, PhD

American Research
Jeffersonville, IN United States

Marc Buggelsheim, PhD

Advanced Research Institute
Sparks, NV United States

Marc Buggelsheim, PhD

Pulmonary Health Physicians
Syracuse, NY United States

Marc Buggelsheim, PhD

Clinical Research of Gastonia
Gastonia, NC United States

Marc Buggelsheim, PhD

Alpha Research Associates, LLC
Dayton, OH United States

Marc Buggelsheim, PhD

Katy Pulmonary Associates, PA
Houston, TX United States

Marc Buggelsheim, PhD

Element Research Group
San Antonio, TX United States